Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 32Myelodysplastic Syndromes 30Leukemia, Myeloid, Acute 30Multiple Myeloma 24Lymphoma, Non-Hodgkin 24Hodgkin Disease 24Lymphoma 21Leukemia 21Graft vs Host Disease 21Leukemia, Lymphocytic, Chronic, B-Cell 20Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Myeloproliferative Disorders 15Lymphoma, Mantle-Cell 15Neoplasms 14Tuberous Sclerosis 13Lymphoma, Large B-Cell, Diffuse 13Hematologic Neoplasms 12Burkitt Lymphoma 12Primary Myelofibrosis 11Lymphoma, Follicular 11Breast Neoplasms 11Waldenstrom Macroglobulinemia 10Sarcoma 10Recurrence 10Neoplasms, Plasma Cell 10Neoplasm Metastasis 10Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myelomonocytic, Chronic 10Prostatic Neoplasms 9Lymphangioleiomyomatosis 9

Interventions

Sirolimus 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Advanced Solid Cancers × Sirolimus × Clear all
NCT00337376 2014-01-14

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

Yale University

Phase 1 Terminated
23 enrolled

Advanced Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡